November 18, 1997 Dr. Jason S. Aaron Genscan U.S. P.O. Box 28754 Santa Fe, NM 87592-8724 Dear Dr. Aaron, This letter is to confirm our conversation today. As we discussed, you will forward all personnel files, project schedules and top line project summaries to the above address by December 5. As this project has now become a priority for national security, all current building, employee, and technical security measures will be carefully reviewed at the highest level. A full report outlining all required changes will be sent to you by the end of next week. At the very least you should expect that those employees retained to continue this phase of the research will experience the expected inconvenience of this highest level of security clearance required. Independent travel will be restricted and communications outside of the immediate facility will be curtailed and completely monitored. We are developing an incentive package we feel will inspire the scientists to continue the work. It would be a pity to lose the momentum gained thus far. We will provide high level profit sharing as well as preferred stock options so they can participate in the increased economic activity expected. We urge you to present this transition in the most positive of lights. Given the implications, termination will not be as pleasant. As we both know, the established market is huge. But, this protocol will provide total market share dominance as long as the technology is not co-opted. We are, as yet, unable to predict the duration of the antidote research. In the meantime, we will be looking at mergers and acquisitions to protect the charter we are creating. We look forward to working with you on this project. Sincerely, Dr. Alex Eaton, EMR Research